Suven Secures Product Patents from China, USA | CORPORATE ETHOS

Suven Secures Product Patents from China, USA

By: | June 12, 2018
suven life sciences

Jun 12: Suven Life Sciences Ltd on Tuesday announced that the company has been granted one product patent from China (CN105814020) and another  one product patent from USA (9957257) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2036 respectively.

According to the company, the granted claims of the patents include the class of selective 5-HT4 and 5 HT6 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia etc.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.

Suven shares were trading at Rs 232.10, up 2.54% from the previous closing of Rs 226.35, on BSE at 3.35 pm today.